Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
FBIO 
Fortress Biotech Inc (FBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: FBIO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10.75
1 Year Target Price $10.75
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -73.98% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 87.53M USD | Price to earnings Ratio - | 1Y Target Price 10.75 |
Price to earnings Ratio - | 1Y Target Price 10.75 | ||
Volume (30-day avg) 2 | Beta 1.51 | 52 Weeks Range 1.33 - 4.20 | Updated Date 12/1/2025 |
52 Weeks Range 1.33 - 4.20 | Updated Date 12/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.12 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-14 | When - | Estimate -0.01 | Actual 0.11 |
Profitability
Profit Margin 6.4% | Operating Margin (TTM) -38.63% |
Management Effectiveness
Return on Assets (TTM) -34.25% | Return on Equity (TTM) -205.29% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 69604982 | Price to Sales(TTM) 1.4 |
Enterprise Value 69604982 | Price to Sales(TTM) 1.4 | ||
Enterprise Value to Revenue 1.12 | Enterprise Value to EBITDA -0.29 | Shares Outstanding 31037937 | Shares Floating 23451334 |
Shares Outstanding 31037937 | Shares Floating 23451334 | ||
Percent Insiders 20.12 | Percent Institutions 15.05 |
Upturn AI SWOT
Fortress Biotech Inc
Company Overview
History and Background
Fortress Biotech Inc. was founded in 2006. It's a biopharmaceutical company focused on acquiring, developing, and commercializing pharmaceutical and biotechnology products. It operates through multiple subsidiary companies.
Core Business Areas
- Pharmaceutical Development: Focuses on developing and commercializing pharmaceutical products. This includes novel therapeutics and reformulations of existing drugs.
- Biotechnology: Involves research and development of biotechnology products, often through subsidiary companies or partnerships.
- Commercialization: Involves marketing and selling approved pharmaceutical products.
Leadership and Structure
The leadership team consists of senior executives responsible for strategy, finance, research and development, and commercial operations. The organizational structure includes subsidiary companies that operate with some degree of autonomy while being overseen by the parent company, Fortress Biotech.
Top Products and Market Share
Key Offerings
- Dermatology Products: Fortress markets a portfolio of dermatology products through its subsidiaries. Market share varies widely by specific product. Competitors include Galderma, Bausch Health, and various generic manufacturers. Revenue is typically undisclosed.
- Oncology Products: Fortress is developing and commercializing products for various cancers. Market share is often small initially, with potential for growth upon successful clinical trials and regulatory approval. Competitors vary based on specific cancer type. Revenue is typically undisclosed, early stage.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and significant regulatory hurdles. Competition is intense, and innovation is crucial.
Positioning
Fortress Biotech Inc. is positioned as a company that acquires and develops promising pharmaceutical and biotechnology assets. Its competitive advantage lies in its business model of creating and managing subsidiary companies, which allows for focused development efforts.
Total Addressable Market (TAM)
The global pharmaceutical market is valued at over $1 trillion. Fortress Biotech is positioned within niche therapeutic areas; therefore, capturing even a small percentage translates to substantial growth potential. Its TAM depends on the success of its portfolio of assets in development.
Upturn SWOT Analysis
Strengths
- Diversified portfolio of subsidiary companies
- Experienced management team
- Focus on acquiring and developing promising assets
- Potential for high returns on successful products
Weaknesses
- High reliance on clinical trial success
- Significant debt load
- Dependence on external funding
- Relatively small revenue base
Opportunities
- Acquisition of new assets
- Partnerships with larger pharmaceutical companies
- Successful clinical trial outcomes
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Patent expirations
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- MRK
- ABBV
Competitive Landscape
Fortress Biotech competes with much larger pharmaceutical companies. Its advantage lies in its nimble structure and focus on specific assets, but it faces challenges in competing with the resources and established market presence of larger players.
Major Acquisitions
Avenue Therapeutics
- Year: 2018
- Acquisition Price (USD millions): 18.5
- Strategic Rationale: Acquired Avenue Therapeutics to develop and commercialize IV Tramadol.
Growth Trajectory and Initiatives
Historical Growth: Growth has been dependent on acquisitions and development of existing assets. Historical results have been inconsistent.
Future Projections: Analyst estimates vary widely based on the success of its pipeline. Refer to analyst reports for specific projections.
Recent Initiatives: Recent initiatives include acquiring new companies, advancing clinical trials, and seeking regulatory approvals.
Summary
Fortress Biotech is a higher-risk, higher-reward biopharmaceutical company with a diverse portfolio of assets under development. Its success hinges on clinical trial outcomes and regulatory approvals. Its decentralized structure can be beneficial, but debt levels and dependence on future financing pose challenges. Investors should watch for successful product commercialization to increase revenue. The company operates in a very competitive landscape amongst large pharmaceuticals with enormous resources.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Analyst Reports
- Company Website
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share estimates may be approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fortress Biotech Inc
Exchange NASDAQ | Headquaters Bay Harbor Islands, FL, United States | ||
IPO Launch date 2011-11-17 | Executive Chairman, President & CEO Dr. Lindsay Allan Rosenwald M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 101 | Website https://www.fortressbiotech.com |
Full time employees 101 | Website https://www.fortressbiotech.com | ||
Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.